HC Wainwright Has Weak Estimate for CG Oncology Q3 Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for CG Oncology to a loss of $0.96 per share from a previous loss estimate of $0.78, while maintaining a “Buy” rating and $100 price target.
• CG Oncology’s latest quarterly results showed a $0.90-per-share loss, missing the $0.66 consensus estimate, although revenue of $1.16 million exceeded forecasts of $0.36 million.
• Analyst sentiment remains broadly positive, with 11 Buy ratings, two Holds and one Sell, producing a “Moderate Buy” consensus rating and an average price target of $83.18.

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Analysts at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for CG Oncology in a note issued to investors on Thursday, August 6th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.96) per share for the quarter, down from their prior forecast of ($0.78). HC Wainwright has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for CG Oncology's current full-year earnings is ($3.03) per share. HC Wainwright also issued estimates for CG Oncology's Q4 2026 earnings at ($1.03) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($2.83) EPS and FY2028 earnings at ($0.65) EPS.

Several other equities analysts have also recently issued reports on CGON. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CG Oncology in a research note on Friday, July 17th. JPMorgan Chase & Co. increased their target price on shares of CG Oncology from $91.00 to $96.00 and gave the company an "overweight" rating in a research note on Monday, May 11th. Royal Bank Of Canada reduced their target price on shares of CG Oncology from $81.00 to $79.00 and set an "outperform" rating for the company in a report on Friday. Piper Sandler lifted their price target on shares of CG Oncology from $82.00 to $85.00 and gave the stock an "overweight" rating in a research report on Friday. Finally, Wall Street Zen cut CG Oncology from a "sell" rating to a "strong sell" rating in a report on Saturday. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $83.18.

CG Oncology Stock Performance

Shares of CG Oncology stock opened at $75.10 on Monday. CG Oncology has a 52 week low of $23.65 and a 52 week high of $77.00. The stock has a market cap of $6.66 billion, a PE ratio of -27.92 and a beta of 0.23. The company's 50-day moving average price is $67.12 and its two-hundred day moving average price is $64.02.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.24). The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.36 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 26.58%.

Insiders Place Their Bets

In other CG Oncology news, Director Leonard E. Post sold 5,000 shares of the company's stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total transaction of $350,000.00. Following the completion of the sale, the director directly owned 5,000 shares of the company's stock, valued at approximately $350,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brian Guan-Chyun Liu bought 371,085 shares of the company's stock in a transaction dated Thursday, June 25th. The stock was purchased at an average cost of $66.87 per share, for a total transaction of $24,814,453.95. Following the completion of the transaction, the director owned 1,886,236 shares of the company's stock, valued at $126,132,601.32. This represents a 24.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have sold 37,129 shares of company stock worth $2,663,817. Company insiders own 4.80% of the company's stock.

Hedge Funds Weigh In On CG Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of CG Oncology in the second quarter valued at $444,509,000. Wellington Management Group LLP boosted its position in shares of CG Oncology by 8.8% in the fourth quarter. Wellington Management Group LLP now owns 5,999,790 shares of the company's stock worth $249,111,000 after buying an additional 487,011 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of CG Oncology by 116.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company's stock valued at $142,961,000 after buying an additional 1,854,386 shares in the last quarter. State Street Corp grew its holdings in shares of CG Oncology by 46.4% during the fourth quarter. State Street Corp now owns 2,996,695 shares of the company's stock valued at $124,423,000 after buying an additional 950,028 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in CG Oncology by 15.0% during the second quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company's stock valued at $56,270,000 after buying an additional 281,637 shares during the period. Institutional investors and hedge funds own 26.56% of the company's stock.

Trending Headlines about CG Oncology

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $82 to $85 and assigned an “overweight” rating, implying approximately 13.2% upside. Benzinga
• Positive Sentiment: Truist Financial also raised its target from $82 to $85 and upgraded its view to “buy,” citing a more constructive outlook for CG Oncology. The Fly
• Positive Sentiment: HC Wainwright maintained a “buy” rating and a $100 target. The firm modestly increased its long-term FY2030 EPS forecast to $6.88 from $6.77, reinforcing expectations for significant future earnings growth as the company advances its pipeline. MarketBeat
• Positive Sentiment: CG Oncology reported second-quarter revenue of $1.16 million, substantially above the $0.36 million consensus estimate, while also highlighting pipeline and business progress. CG Oncology Second-Quarter Results
• Neutral Sentiment: Royal Bank of Canada lowered its target from $81 to $79 but retained an “outperform” rating. The reduced target still represents roughly 5.2% potential upside and may reflect valuation calibration rather than a fundamental downgrade. Ticker Report
• Negative Sentiment: CG Oncology reported a quarterly loss of $0.90 per share, wider than the $0.66 consensus loss and the $0.54 loss recorded a year earlier. The earnings shortfall could limit gains despite strong analyst targets. Zacks Q2 Earnings Report
• Negative Sentiment: HC Wainwright reduced its FY2029 EPS estimate from $2.43 to $2.34, signaling some moderation in its intermediate-term earnings outlook, although its buy rating and $100 target remain unchanged.

CG Oncology Company Profile

CG Oncology, Inc NASDAQ: CGON is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source